PANSEC 20 20MG TABLET

Indications

• Chronic pain management
• Gastroesophageal reflux disease (GERD)
• Irritable bowel syndrome
• Attention-deficit hyperactivity disorder (ADHD) management
• Chronic respiratory conditions requiring bronchodilation

Dosage

Children: Refer to specific product labeling or clinical guidelines for paediatric dosing information.

Adults: Refer to specific product labeling or clinical guidelines for adult dosing information.

Mechanism of action

The mechanism of action varies depending on the specific drug formulation. Generally, delayed-release formulations are designed to dissolve at a specific site in the gastrointestinal tract, allowing for a slower absorption process. This can enhance the drug's therapeutic effects while minimizing side effects associated with peak plasma concentrations.

Pharmacodynamics

The pharmacodynamics of delayed-release medications involve the interaction between the drug and its target receptors or enzymes over a prolonged period. This can lead to sustained therapeutic effects, reduced frequency of dosing, and improved patient adherence to treatment regimens. The slow release mechanism also helps in maintaining more stable plasma drug concentrations, potentially reducing the occurrence of adverse effects.

Pharmacokinetics

Pharmacokinetics of delayed-release drugs typically include altered absorption rates due to the formulation's design. The onset of action may be delayed compared to immediate-release formulations. The distribution, metabolism, and excretion of the drug will depend on its chemical properties, but generally, the half-life may be extended due to prolonged absorption. Many delayed-release formulations utilize polymers or other excipients that control the release rate of the active ingredient.

Pregnancy

The safety of delayed-release formulations during pregnancy has not been well established. Consultation with a healthcare provider is recommended.

Breast-feeding

Caution is advised when using delayed-release medications while breastfeeding, as effects on the infant are unknown.

Storage

Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.

Indications

• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease
• Zollinger-Ellison syndrome
• Erosive esophagitis associated with acid reflux

Dosage

Children: Refer to the BNF for Children for pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated.

Mechanism of action

Pantoprazole works by covalently binding to the H+/K+ ATPase enzyme in the gastric parietal cells, leading to irreversible inhibition of the proton pump. This action significantly reduces the production of gastric acid, resulting in increased gastric pH.

Pharmacodynamics

The pharmacodynamic effects of pantoprazole include a rapid decrease in gastric acidity following administration. The onset of action is typically observed within one hour, with peak effects reached after about two to four hours. The duration of acid suppression can last for up to 24 hours, allowing for effective control of gastric acidity.

Pharmacokinetics

Pantoprazole is well absorbed after oral administration, with peak plasma concentrations occurring approximately 2 to 4 hours post-dose. It undergoes extensive hepatic metabolism, primarily by the cytochrome P450 system, with a half-life of about 1 hour. The elimination occurs mainly via urine and feces, with less than 1% excreted unchanged. Its bioavailability is increased with repeated dosing due to reduced first-pass metabolism.

Contra-indications

• Hypersensitivity to pantoprazole or any component of the formulation.
• Concurrent use with atazanavir.

Adverse effects

• Headache
• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Constipation
• Flatulence
• Rash
• Dizziness
• Fatigue

Interactions

• May reduce the absorption of drugs requiring an acidic environment for optimal bioavailability, such as ketoconazole and atazanavir.
• Caution when used with anticoagulants, as pantoprazole may affect INR.
• May increase the plasma levels of methotrexate.

Precautions

• Use with caution in patients with hepatic impairment.
• Long-term use may be associated with an increased risk of gastrointestinal infections.
• Monitor magnesium levels in patients on prolonged therapy.

Pregnancy

Animal studies have shown no reproductive toxicity, but data in humans is limited. Use only if clearly needed.

Breast-feeding

Pantoprazole is excreted in human milk; caution is advised when administering to nursing mothers.

Storage

Store below 25 degrees Celsius. Protect from light and moisture.

Formulations

• Tablets: 20 mg, 40 mg
• Injection: 40 mg (as pantoprazole sodium)

Indications

• Bacterial infections
• Infections caused by susceptible organisms
• Prophylaxis in certain surgical procedures

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations based on age, weight, and condition.

Adults: Refer to the BNF for specific dosages based on the condition being treated, severity of infection, and patient factors.

Mechanism of action

Release exerts its effects by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. This mechanism is primarily mediated through the disruption of peptidoglycan cross-linking, which is essential for maintaining the structural integrity of bacterial cell walls.

Pharmacodynamics

The pharmacodynamics of Release involves its bactericidal action against a wide range of gram-positive and some gram-negative bacteria. The drug displays a time-dependent killing effect, meaning that its efficacy is related to the duration of exposure rather than the peak concentration achieved. Resistance to Release can develop through various mechanisms, including alterations in target sites or enzymatic degradation.

Pharmacokinetics

Release is absorbed and distributed throughout the body following administration. Peak plasma concentrations are typically achieved within a few hours. The drug is metabolized primarily in the liver, with metabolites excreted via the kidneys. The half-life of Release can vary depending on individual patient factors, including age, liver function, and concurrent medications.